As with the originally identified oncogenic fusion, research on ABL inhibitors is ongoing, with the development of new drugs to effectively treat CML proceeding concurrently [46]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.